News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acumen Pharmaceuticals Inc. Announces Amended Agreement With Merck & Co., Inc. (MRK) To Include Exclusive Diagnostic Rights



11/27/2006 3:39:57 PM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acumen Pharmaceuticals, a leading pre-clinical biotech company working in Alzheimer’s therapeutics, today announced that it has amended its existing license agreement with Merck & Co., Inc. to grant an exclusive license to research and develop amyloid-derived diffusible ligand (ADDL) directed diagnostic products.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES